| Tumor mutational load predicts survival after immunotherapy across multiple cancer types RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ... Nature genetics 51 (2), 202-206, 2019 | 3099 | 2019 |
| IDH mutation impairs histone demethylation and results in a block to cell differentiation C Lu, PS Ward, GS Kapoor, D Rohle, S Turcan, O Abdel-Wahab, ... Nature 483 (7390), 474-478, 2012 | 2147 | 2012 |
| IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype S Turcan, D Rohle, A Goenka, LA Walsh, F Fang, E Yilmaz, C Campos, ... Nature 483 (7390), 479-483, 2012 | 2117 | 2012 |
| Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors IK Mellinghoff, MY Wang, I Vivanco, DA Haas-Kogan, S Zhu, EQ Dia, ... New England Journal of Medicine 353 (19), 2012-2024, 2005 | 1724 | 2005 |
| An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells D Rohle, J Popovici-Muller, N Palaskas, S Turcan, C Grommes, ... Science 340 (6132), 626-630, 2013 | 1269 | 2013 |
| Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR MS Neshat, IK Mellinghoff, C Tran, B Stiles, G Thomas, R Petersen, ... Proceedings of the National Academy of Sciences 98 (18), 10314-10319, 2001 | 1237 | 2001 |
| Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma R Beroukhim, G Getz, L Nghiemphu, J Barretina, T Hsueh, D Linhart, ... Proceedings of the National Academy of Sciences 104 (50), 20007-20012, 2007 | 1235 | 2007 |
| High-throughput oncogene mutation profiling in human cancer RK Thomas, AC Baker, RM DeBiasi, W Winckler, T LaFramboise, WM Lin, ... Nature genetics 39 (3), 347-351, 2007 | 1163 | 2007 |
| A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle MF Kircher, A De La Zerda, JV Jokerst, CL Zavaleta, PJ Kempen, E Mittra, ... Nature medicine 18 (5), 829-834, 2012 | 1154 | 2012 |
| Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma TF Cloughesy, AY Mochizuki, JR Orpilla, W Hugo, AH Lee, TB Davidson, ... Nature medicine 25 (3), 477-486, 2019 | 1100 | 2019 |
| Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions PY Wen, M Weller, EQ Lee, BM Alexander, JS Barnholtz-Sloan, ... Neuro-oncology 22 (8), 1073-1113, 2020 | 711 | 2020 |
| Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer GV Thomas, C Tran, IK Mellinghoff, DS Welsbie, E Chan, B Fueger, ... Nature medicine 12 (1), 122-127, 2006 | 691 | 2006 |
| Challenges to curing primary brain tumours K Aldape, KM Brindle, L Chesler, R Chopra, A Gajjar, MR Gilbert, ... Nature reviews Clinical oncology 16 (8), 509-520, 2019 | 678 | 2019 |
| Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma TF Cloughesy, K Yoshimoto, P Nghiemphu, K Brown, J Dang, S Zhu, ... PLoS medicine 5 (1), e8, 2008 | 666 | 2008 |
| Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer L Regales, Y Gong, R Shen, E de Stanchina, I Vivanco, A Goel, ... The Journal of clinical investigation 119 (10), 3000-3010, 2009 | 476 | 2009 |
| Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid AM Miller, RH Shah, EI Pentsova, M Pourmaleki, S Briggs, N Distefano, ... Nature 565 (7741), 654-658, 2019 | 457 | 2019 |
| An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR–dependent pathway D Guo, F Reinitz, M Youssef, C Hong, D Nathanson, D Akhavan, D Kuga, ... Cancer discovery 1 (5), 442-456, 2011 | 449 | 2011 |
| Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation LGT Morris, AM Kaufman, Y Gong, D Ramaswami, LA Walsh, Ş Turcan, ... Nature genetics 45 (3), 253-261, 2013 | 435 | 2013 |
| AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression JF Gera, IK Mellinghoff, Y Shi, MB Rettig, C Tran, J Hsu, CL Sawyers, ... Journal of Biological Chemistry 279 (4), 2737-2746, 2004 | 429 | 2004 |
| Somatic mutations of the Parkinson's disease–associated gene PARK2 in glioblastoma and other human malignancies S Veeriah, BS Taylor, S Meng, F Fang, E Yilmaz, I Vivanco, ... Nature genetics 42 (1), 77-82, 2010 | 416 | 2010 |
